Ideaya Biosciences Inc (Ideaya) is a precision medicine company that develops oncology therapeutics. The company’s product pipeline includes darovasertib (IDE196), a protein kinase C (PKC) inhibitor that targets cancers with GNAQ and GNA11 mutations. It develops small molecule inhibitors based on synthetic lethality against known and novel targets. Ideaya also provides solutions for treating tumors with genetic mutations in homologous recombination deficiency(HRD) and high microsatellite instability (MSI). The company collaborates with Novartis Institute for Biomedical Research, Pfizer Inc, Boston Children’s Hospital, Cancer Research UK, and other academic and research institutes for cancer biology, immunology, and small molecule drug discovery. Ideaya is headquartered in South San Francisco, California, the US.
Ideaya Biosciences Inc premium industry data and analytics
Products and Services
Products |
---|
Pipelines: |
Darovasertib (IDE196) |
PKC Inhibitor |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Ideaya Biosciences Inc | MEI Pharma Inc | Alaunos Therapeutics Inc | ProLynx LLC |
---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America |
City | South San Francisco | San Diego | Houston | San Francisco |
State/Province | California | California | Texas | California |
No. of Employees | 124 | 46 | 1 | 10 |
Entity Type | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Timothy M. Shannon | Chairman | Executive Board | 2016 | 64 |
Yujiro S. Hata | Director; President; Chief Executive Officer | Executive Board | 2015 | 48 |
Paul A. Stone | Chief Financial Officer | Senior Management | 2019 | 59 |
Paul A. Barsanti | Chief Technology Officer | Senior Management | - | - |
Jason S. Throne | Secretary; Chief Legal Officer | Senior Management | 2023 | 52 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer